Global Blood Therapeutics Inc. [NASDAQ: GBT] traded at a high on 08/04/21, posting a 19.97 gain after which it closed the day’ session at $32.26. The company report on August 4, 2021 that GBT Announces Participation at the Wedbush PacGrow Healthcare Conference.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced that it will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021, at 2:20 p.m. ET.
The fireside chat will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event.
The results of the trading session contributed to over 3873462 shares changing hands. Over the past one week, the price volatility of Global Blood Therapeutics Inc. stands at 4.62% while the volatility over the past one month is 4.28%.
The market cap for GBT stock reached $2.05 billion, with 62.10 million shares outstanding and 55.70 million shares in the current float. Compared to the average trading volume of 1.16M shares, GBT reached a trading volume of 3873462 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Global Blood Therapeutics Inc. [GBT]?
Truist have made an estimate for Global Blood Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 04, 2021. While these analysts kept the previous recommendation, JP Morgan dropped their target price from $70 to $36. The new note on the price target was released on June 28, 2021, representing the official price target for Global Blood Therapeutics Inc. stock. Previously, the target price had yet another raise to $54, while SVB Leerink analysts kept a Outperform rating on GBT stock.
The Average True Range (ATR) for Global Blood Therapeutics Inc. is set at 1.77, with the Price to Sales ratio for GBT stock in the period of the last 12 months amounting to 13.80. The Price to Book ratio for the last quarter was 5.51, with the Price to Cash per share for the same quarter was set at 7.58.
How has GBT stock performed recently?
Global Blood Therapeutics Inc. [GBT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.75. With this latest performance, GBT shares dropped by -3.53% in over the last four-week period, additionally sinking by -35.49% over the last 6 months – not to mention a drop of -53.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GBT stock in for the last two-week period is set at 53.51, with the RSI for the last a single of trading hit 61.82, and the three-weeks RSI is set at 49.13 for Global Blood Therapeutics Inc. [GBT]. The present Moving Average for the last 50 days of trading for this stock 34.68, while it was recorded at 28.43 for the last single week of trading, and 42.18 for the last 200 days.
Global Blood Therapeutics Inc. [GBT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Global Blood Therapeutics Inc. [GBT] shares currently have an operating margin of -197.21 and a Gross Margin at +89.65. Global Blood Therapeutics Inc.’s Net Margin is presently recorded at -199.96.
Return on Total Capital for GBT is now -35.50, given the latest momentum, and Return on Invested Capital for the company is -36.17. Return on Equity for this stock declined to -49.77, with Return on Assets sitting at -32.57. When it comes to the capital structure of this company, Global Blood Therapeutics Inc. [GBT] has a Total Debt to Total Equity ratio set at 55.95. Additionally, GBT Total Debt to Total Capital is recorded at 35.88, with Total Debt to Total Assets ending up at 32.16. Long-Term Debt to Equity for the company is recorded at 54.78, with the Long-Term Debt to Total Capital now at 35.13.
Reflecting on the efficiency of the workforce at the company, Global Blood Therapeutics Inc. [GBT] managed to generate an average of -$636,383 per employee. Receivables Turnover for the company is 12.30 with a Total Asset Turnover recorded at a value of 0.16.Global Blood Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.70 and a Current Ratio set at 9.50.
Earnings analysis for Global Blood Therapeutics Inc. [GBT]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GBT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Global Blood Therapeutics Inc. go to 37.00%.
Insider trade positions for Global Blood Therapeutics Inc. [GBT]
There are presently around $2,160 million, in the hands of institutional investors. The top three institutional holders of GBT stocks are: BANK OF AMERICA CORP /DE/ with ownership of 6,203,069, which is approximately 2.256% of the company’s market cap and around 1.90% of the total institutional ownership; JANUS HENDERSON GROUP PLC, holding 5,882,575 shares of the stock with an approximate value of $189.77 million in GBT stocks shares; and VANGUARD GROUP INC, currently with $179.91 million in GBT stock with ownership of nearly 2.129% of the company’s market capitalization.
Positions in Global Blood Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 85 institutional holders increased their position in Global Blood Therapeutics Inc. [NASDAQ:GBT] by around 9,785,921 shares. Additionally, 131 investors decreased positions by around 6,687,748 shares, while 28 investors held positions by with 50,470,414 shares. The mentioned changes placed institutional holdings at 66,944,083 shares, according to the latest SEC report filing. GBT stock had 22 new institutional investments in for a total of 1,624,020 shares, while 38 institutional investors sold positions of 1,410,716 shares during the same period.